Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng Deng

Showing results (461-470 of 463) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 463 results.
The Journal of Clinical Investigation|October 6, 2022
RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancerPeng Deng, Zining Wang, Jinghong Chen, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Clinical Epigenetics|February 5, 2023
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamideJinghong Chen, Zhixiang Zuo, Yan Gao, et al.
Pageof 47

Showing results (461-470 of 463) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 463 results.
The Journal of Clinical Investigation|October 6, 2022
RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancerPeng Deng, Zining Wang, Jinghong Chen, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Clinical Epigenetics|February 5, 2023
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamideJinghong Chen, Zhixiang Zuo, Yan Gao, et al.
Pageof 47